Sara Tolaney
萨拉·托拉尼
MD, MPH
Chief of Breast Oncology, Associate Director of Susan F. Smith Center乳腺肿瘤科主任，苏珊·史密斯中心副主任
👥Biography 个人简介
Sara Tolaney is a foremost expert in HER2-positive and HER2-low breast cancer at Dana-Farber. She led pivotal trials of T-DM1, T-DXd, and tucatinib, fundamentally redefining treatment for HER2-driven disease and establishing HER2-low as a distinct therapeutic category.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
HER2-Low Breast Cancer Treatment
Instrumental in DESTINY-Breast04 and related trials, establishing trastuzumab deruxtecan as standard-of-care for HER2-low metastatic breast cancer.
Early HER2+ Adjuvant Therapy
Led the APT trial, establishing weekly paclitaxel plus trastuzumab as a standard low-risk HER2+ adjuvant regimen with excellent outcomes.
Representative Works 代表性著作
Adjuvant paclitaxel and trastuzumab for HER2-positive, node-negative breast cancer (APT trial)
New England Journal of Medicine (2015)
Defined a less toxic adjuvant standard for low-risk HER2+ breast cancer, influencing global practice guidelines.
Trastuzumab deruxtecan in HER2-low breast cancer (DESTINY-Breast04)
New England Journal of Medicine (2022)
Pivotal trial establishing T-DXd benefit in HER2-low disease, creating a new breast cancer subtype and treatment paradigm.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 萨拉·托拉尼 的研究动态
Follow Sara Tolaney's research updates
留下邮箱，当我们发布与 Sara Tolaney（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment